<i>In vivo</i> tumor cell rejection induced by NK cell inhibitory receptor blockade: Maintained tolerance to normal cells even in the presence of IL‐2
Gustaf Vahlne(Karolinska Institutet), Maria H. Johansson(Universität Innsbruck), Anders Meier(Novo Nordisk (Denmark)), Frank R. Brennan(AstraZeneca (United Kingdom)), Tadepally Lakshmikanth(Hammersmith Hospital), Klas Kärre(Karolinska Institutet), Stina L. Wickström(Karolinska Institutet), Michael Wilken(Novo Nordisk (Denmark)), Katja Lindholm(Karolinska Institutet), Rikke Nielsen(Aarhus University), Nicolai Wagtmann(Howard Hughes Medical Institute), François Romagné(Innate Pharma (France))
Cited by 35